[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593152":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":40,"responsibleParty":55,"collaborators":26,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":26,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":26,"enrollmentInfo":66,"targetDuration":26,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":26,"overallStatus":42,"whyStopped":26,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Peking University Shenzhen Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Esketamine combined with dexmedetomidine group","EXPERIMENTAL","After successful neuraxial anesthesia, 0.125mg\u002Fkg esketamine and 0.3ug\u002Fkg dexmedetomidine were diluted into 30ml of normal saline and continuously pumped for 20 minutes, followed by a micropump: 15ug\u002Fkg\u002Fh esketamine 0.02ug\u002Fkg\u002Fh dexmedetomidine to 96ml saline, continuous amount: 2ml\u002Fh, continuous pumping for 48h.",[13],"Drug: Esketamine combined with dexmedetomidine",{"label":15,"type":16,"description":17,"interventionNames":18},"Normal saline group","PLACEBO_COMPARATOR","After successful neuraxial anesthesia, 30ml of normal saline was continuously pumped for 20 minutes, followed by a micropump: 96ml of saline, continuous amount: 2ml\u002Fh for 48h.",[19],"Drug: Normal saline",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Esketamine combined with dexmedetomidine","After successful neuraxial anesthesia, 0.125mg\u002Fkg esketamine and 0.3ug\u002Fkg dexmedetomidine are diluted into 30ml of normal saline and continuously pumped for 20 minutes, then connected to a micropump: 15ug\u002Fkg\u002Fh esketamine 0.02ug\u002Fkg\u002Fh dexmedetomidine to 96ml saline, continuous amount: 2ml\u002Fh, continuous pumping for 48h.",[9],null,{"type":22,"name":28,"description":17,"armGroupLabels":29,"otherNames":26},"Normal saline",[15],[31],{"name":32,"affiliation":33,"role":34},"Tao Luo, MD,PhD","Peking University Shenzhen Hospitai","PRINCIPAL_INVESTIGATOR",[36],{"name":32,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","13510820779","luotao_wh@yahoo.com",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":26,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Shenzhen","Guangdong","China","CN",{"type":48,"coordinates":49},"Point",[50,51],114.0683,22.54554,{"lat":51,"lon":50},[54],{"name":32,"role":37,"phone":38,"phoneExt":26,"email":39},{"type":56,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100593152","effects-of-esketamine-combined-with-dexmedetomidine-on-postoperative-sleep-quality-100593152",false,"NCT07002723","Effects of Esketamine Combined With Dexmedetomidine on Postoperative Sleep Quality","Effects of Esketamine Combined With Dexmedetomidine on Postoperative Sleep Quality in Elderly Patients Undergoing Hip Surgery:A Superiority Randomized Controlled Trail","Inclusion Criteria:\n\n* Age≥ 65 years old;\n* Hip fracture surgery under neuraxial anesthesia;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* ASA classification≥ Class V;\n* Presence of neuraxial anesthesia contraindications: coagulation dysfunction, thrombocytopenia, neuraxial mass, puncture site infection, etc.;\n* Patients with contraindications to esketamine (such as allergies, intracranial aneurysms, hyperthyroidism and glaucoma);\n* Patients with contraindications to dexmedetomidine (allergies);\n* Patients with severe cardiovascular diseases such as sick sinus syndrome, severe sinus bradycardia (heart rate \\\u003C 50 beats\u002Fmin), atrioventricular block grade II or above without pacemaker, unstable angina, severe valvular heart disease, severe arrhythmia, severe macrovascular disease with New York Heart Association class III patients, etc.;\n* Obstructive sleep apnea syndrome (STOP-BANG score \\> 3 points);\n* Patients with severe hepatic and renal insufficiency (such as Child-Pugh score III, creatinine clearance \\\u003C 35 mL\u002Fmin, preoperative dialysis);\n* Those who have delirium, dementia, moderate to severe cognitive dysfunction and psychiatric disorders before the start of the trial and are unable to communicate and cooperate with the investigator.","ALL","65 Years",{"count":67,"type":68},96,"ESTIMATED","INTERVENTIONAL",[71],"NA","1. Eligible patients are randomly divided into experimental and control groups；\n2. The experimental group is given esketamine combined with dexmedetomidine，while the control group is given normal saline；\n3. The patients' sleep, pain, and cognition are followed up after surgery.",[74],"Hip Fractures","2025-11-30",{"date":77,"type":78},"2025-12-05","ACTUAL",{"date":80,"type":78},"2025-06-20",{"date":82,"type":68},"2026-06-30",{"name":5,"class":6},1]